ID   DiFi
AC   CVCL_6895
SY   DIFI
DR   BTO; BTO:0005902
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 856
DR   cancercelllines; CVCL_6895
DR   Cell_Model_Passport; SIDM00049
DR   Cosmic; 1479628
DR   Cosmic; 1519358
DR   Cosmic; 2841360
DR   Cosmic-CLP; 1789883
DR   DepMap; ACH-002233
DR   EGA; EGAS00001000978
DR   GDSC; 1789883
DR   GEO; GSM1448175
DR   GEO; GSM1669732
DR   KCB; KCB 2014033YJ
DR   PharmacoDB; DIFI_291_2019
DR   PRIDE; PXD005235
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_6895
DR   Wikidata; Q54831091
RX   DOI=10.1007/978-4-431-68337-7_80;
RX   PubMed=8385096;
RX   PubMed=20570890;
RX   PubMed=22270724;
RX   PubMed=22722830;
RX   PubMed=25623215;
RX   PubMed=25926053;
RX   PubMed=27397505;
RX   PubMed=28854368;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: ~40 hours (PubMed=8385096).
CC   Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu443fs*16 (c.1328_1329delAA); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1151Ter (c.3451G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=2.91%; Native American=0.44%; East Asian, North=1.85%; East Asian, South=0%; South Asian=0%; European, North=54.25%; European, South=40.55% (PubMed=30894373).
CC   Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0002000000030). It was one of the sources for the STR profile of this entry.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): CCRID; Cosmic-CLP; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,11
ST   D16S539: 12
ST   D18S51: 13
ST   D21S11: 32
ST   D3S1358: 17,18
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   D8S1179: 12
ST   FGA: 23,27
ST   Penta D: 12
ST   Penta E: 12,18
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 17,18
DI   NCIt; C2955; Colorectal carcinoma
DI   NCIt; C6728; Gardner syndrome
DI   ORDO; Orphanet_79665; Gardner syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   46Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 30
//
RX   DOI=10.1007/978-4-431-68337-7_80;
RA   Boman B.M., Olive M., Untawale S., Blick M., North S., Gallick G.E.,
RA   Dolf G., Siciliano M.J., Roubein L.D., Fritche H., Thomas G.,
RA   Pathak S., Wildrick D.M., Levin B.;
RT   "The DiFi rectal carcinoma cell line from a familial adenomatous
RT   polyposis patient: an in vitro model system to study genetic changes
RT   in colorectal cancer.";
RL   (In) Hereditary colorectal cancer; Utsunomiya J., Lynch H.T. (eds.); pp.541-548; Springer; Tokyo (1990).
//
RX   PubMed=8385096; DOI=10.1007/BF02634191;
RA   Olive M., Untawale S., Coffey R.J., Siciliano M.J., Wildrick D.M.,
RA   Fritsche H., Pathak S., Cherry L.M., Blick M., Lointier P.,
RA   Roubein L.D., Levin B., Boman B.M.;
RT   "Characterization of the DiFi rectal carcinoma cell line derived from
RT   a familial adenomatous polyposis patient.";
RL   In Vitro Cell. Dev. Biol. Anim. 29:239-248(1993).
//
RX   PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192;
RA   Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S.,
RA   Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M.,
RA   Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M.,
RA   Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.;
RT   "Genomic and biological characterization of exon 4 KRAS mutations in
RT   human cancer.";
RL   Cancer Res. 70:5901-5911(2010).
//
RX   PubMed=22270724; DOI=10.1038/nm.2609;
RA   Montagut C., Dalmases A., Bellosillo B., Crespo M., Pairet S.,
RA   Iglesias M., Salido M., Gallen M., Marsters S., Tsai S.-P., Minoche A.,
RA   Seshagiri S., Serrano S., Himmelbauer H., Bellmunt J., Rovira A.,
RA   Settleman J., Bosch F., Albanell J.;
RT   "Identification of a mutation in the extracellular domain of the
RT   epidermal growth factor receptor conferring cetuximab resistance in
RT   colorectal cancer.";
RL   Nat. Med. 18:221-223(2012).
//
RX   PubMed=22722830; DOI=10.1038/nature11156;
RA   Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D.,
RA   Valtorta E., Schiavo R., Buscarino M., Siravegna G., Bencardino K.,
RA   Cercek A., Chen C.-T., Veronese S., Zanon C., Sartore-Bianchi A.,
RA   Gambacorta M., Gallicchio M., Vakiani E., Boscaro V., Medico E.,
RA   Weiser M.R., Siena S., Di Nicolantonio F., Solit D.B., Bardelli A.;
RT   "Emergence of KRAS mutations and acquired resistance to anti-EGFR
RT   therapy in colorectal cancer.";
RL   Nature 486:532-536(2012).
//
RX   PubMed=25623215; DOI=10.1158/1078-0432.CCR-14-2821;
RA   Arena S., Bellosillo B., Siravegna G., Martinez A., Canadas I.,
RA   Lazzari L., Ferruz N., Russo M., Misale S., Gonzalez I., Iglesias M.,
RA   Gavilan E., Corti G., Hobor S., Crisafulli G., Salido M., Sanchez J.,
RA   Dalmases A., Bellmunt J., De Fabritiis G., Rovira A.,
RA   Di Nicolantonio F., Albanell J., Bardelli A., Montagut C.;
RT   "Emergence of multiple EGFR extracellular mutations during cetuximab
RT   treatment in colorectal cancer.";
RL   Clin. Cancer Res. 21:2157-2166(2015).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010;
RA   Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C.,
RA   Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M.,
RA   Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R.,
RA   Guinney J., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.;
RT   "Genomic determinants of protein abundance variation in colorectal
RT   cancer cells.";
RL   Cell Rep. 20:2201-2214(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//